NCT04033107RecruitingPhase 2
Clinical Research of High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
Zhongnan Hospital1 site in 1 country30 target enrollmentStarted: July 1, 2020Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Progression-free survival
Study Overview
Brief Summary
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of high-dose vitamin C combined with metformin in the treatment of malignant tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years to 75 years.
- •Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1)： Cohort A: patients with advanced hepatocellular carcinoma who had failed previous standard first-line therapy and could not tolerate or reject existing therapies.
- •Cohort B: patients with advanced pancreatic cancer who had previously failed standard first-line therapy, could not tolerate or reject existing therapies.
- •Cohort C: patients with advanced gastric cancer who had failed previous standard second-line or above treatment, who could not tolerate or reject existing therapies.
- •Cohort D: patients with advanced colorectal cancer who had failed previous standard second-line or above treatment, who could not tolerate or reject existing therapies.
- •Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥80g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.5×the upper limit of normal(ULN), ALT and AST≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate > 50ml/min).
- •At least 4 weeks after the last anti-tumor treatment (surgery, chemotherapy, radiotherapy, biotherapy or endocrine therapy) before enrollment.
- •Had a life expectancy of at least 3 months.
- •Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or
- •Signed informed consent.
Exclusion Criteria
- •In the past or at the same time with other malignant tumors (already cure period of IB or cervical, lower levels of noninvasive basal cell or squamous cell cancer, obtain complete remission (CR) > 10 years of breast cancer, obtain complete remission (CR) > 10 years of malignant melanoma, obtain complete remission (CR) > 5 years except of other malignant tumors).
- •Pregnant or lactating female patients.
- •Those who have applied excessive dose of vitamin C or (and) metformin in recent 1 month.
- •Patients with glucose-6-phosphate dehydrogenase deficiency.
- •Patients with hydronephrosis.
- •Had a history of clinically significant or uncontrolled heart disease, including but not limited to: (1)Myocardial infarction. (2)Angina.(3)Congestive heart failure above grade 2 of the New York heart association (NYHA).(4)Ventricular arrhythmias requiring continuous treatment.(5)Supraventricular arrhythmias, including uncontrolled atrial fibrillation.
- •The patients had mental disorders, and the researchers believed that the patients could not fully or fully understand the possible complications in this study.
- •Have a history of immunodeficiency, including: HIV positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
- •Those who cannot tolerate or may be allergic to the drugs used in this study.
- •Participated in clinical trials of other drugs within the past 1 month.
- •Other factors considered unsuitable for the study.
Arms & Interventions
Treatment arm
Experimental
Vitamin C combined with metformin
Intervention: Vitamin C (Drug)
Treatment arm
Experimental
Vitamin C combined with metformin
Intervention: Metformin (Drug)
Outcomes
Primary Outcomes
Progression-free survival
Time Frame: up to 12 weeks
Defined as time from first dose of treatment to death from any cause, or even radiological detection/or clinical of disease progression.
Secondary Outcomes
- Changes of quality of life(up to 12 weeks)
- Overall survival(up to 12 weeks)
- Objective response rate(up to 12 weeks)
- Disease control rate(up to 12 weeks)
- Number of participants with treatment-related adverse events as assessed by CTCAE v3.0(up to 12 weeks)
Investigators
Zhou Fuxiang
Principal Investigator, Clinical Professor
Zhongnan Hospital
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65
Recruiting
Not Applicable
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological MalignanciesLymphomaMultiple MyelomaNCT05536154The Affiliated People's Hospital of Ningbo University68
Recruiting
Not Applicable
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological MalignanciesHematological MalignancyNCT05510089The Affiliated People's Hospital of Ningbo University62
Recruiting
Phase 1
An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, tiragolumab and stereotactic body radiation therapy in patients with metastatic multiorgan cancer2024-516717-20-00Centr Georges Francois Leclerc86
Recruiting
Not Applicable
Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DESCoronary Artery DiseaseNCT05770674Kiyuk Chang2,186